Clinical Trial Detail

NCT ID NCT04159896
Title ESK981 and Nivolumab for the Treatment of Metastatic Castration Resistant Prostate Cancer
Recruitment Not yet recruiting
Gender male
Phase Phase II
Variant Requirements No
Sponsors Barbara Ann Karmanos Cancer Institute
Indications

prostate cancer

Therapies

CEP-11981 + Nivolumab

Age Groups: senior adult

No variant requirements are available.